AnaptysBio (ANAB) Rating Lowered to Sell at Zacks Investment Research

AnaptysBio (NASDAQ:ANAB) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other equities research analysts have also commented on ANAB. Cantor Fitzgerald set a $124.00 target price on AnaptysBio and gave the company a “buy” rating in a research report on Sunday, September 16th. Jefferies Financial Group restated a “buy” rating and set a $121.00 target price on shares of AnaptysBio in a research report on Tuesday, August 7th. Credit Suisse Group started coverage on AnaptysBio in a research report on Thursday, July 19th. They set an “outperform” rating and a $104.00 target price on the stock. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the company a “buy” rating in a research report on Friday, September 14th. Finally, Wedbush restated an “outperform” rating and set a $138.00 target price on shares of AnaptysBio in a research report on Tuesday, September 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $130.90.

Shares of ANAB stock opened at $81.25 on Wednesday. The stock has a market capitalization of $2.40 billion, a PE ratio of -54.41 and a beta of 2.77. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01. AnaptysBio has a 1-year low of $62.64 and a 1-year high of $134.00.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.13. As a group, research analysts predict that AnaptysBio will post -2.72 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the stock. United Services Automobile Association boosted its position in shares of AnaptysBio by 27.9% during the 2nd quarter. United Services Automobile Association now owns 3,138 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 685 shares in the last quarter. Northern Trust Corp boosted its position in shares of AnaptysBio by 6.7% during the 2nd quarter. Northern Trust Corp now owns 211,150 shares of the biotechnology company’s stock valued at $15,000,000 after purchasing an additional 13,180 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in AnaptysBio by 8.2% in the second quarter. Bank of New York Mellon Corp now owns 83,947 shares of the biotechnology company’s stock worth $5,963,000 after acquiring an additional 6,355 shares in the last quarter. Partner Fund Management L.P. boosted its holdings in AnaptysBio by 96.6% in the second quarter. Partner Fund Management L.P. now owns 138,338 shares of the biotechnology company’s stock worth $9,828,000 after acquiring an additional 67,984 shares in the last quarter. Finally, Partner Investment Management L.P. boosted its holdings in AnaptysBio by 82.8% in the second quarter. Partner Investment Management L.P. now owns 1,709 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 774 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Read More: What is a Tariff?

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply